Login or sign up
For business
Average ratingGreat
4.4/ 5

Based on 7 reviews

557%
429%
314%
20%
10%
Ask AI

Ask Trustburn about Geron

Based on 7 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Dexter Shapiro
Reviews 1

I recently used Geron for the first time, and I must say I was impressed. Their website was easy to use, and their customer service was outstanding. I had a few questions and they were answered promptly. I will definitely be using their services again in the future.

Randy Gates
Reviews 1

I had a great experience with Geron. Their website, geron.com, is easy to navigate and has all the information I needed. The customer service was excellent, and they were able to answer all of my questions quickly and efficiently. I would highly recommend Geron to others.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Geron

Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Geron: Revolutionizing the Treatment of Hematologic Myeloid Malignancies

Geron is a clinical stage biopharmaceutical company that has been at the forefront of developing innovative treatments for hematologic myeloid malignancies. The company's primary focus is on the development of imetelstat, a telomerase inhibitor that has shown promising results in clinical trials.

Hematologic myeloid malignancies are a group of cancers that affect blood-forming cells in the bone marrow. These include diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). These diseases can be difficult to treat, and there is a significant need for new therapies.

Imetelstat works by inhibiting telomerase, an enzyme that plays a key role in cancer cell growth and survival. By targeting telomerase, imetelstat has the potential to slow or even stop the growth of cancer cells. This makes it an exciting prospect for patients with hematologic myeloid malignancies who have few treatment options available.

Geron's commitment to developing imetelstat has led to several successful clinical trials. In one study, patients with MDS who received imetelstat had significantly longer overall survival compared to those who received placebo. Another trial showed promising results in patients with relapsed or refractory AML.

The success of these trials has led Geron to continue its research into imetelstat and explore its potential use in other types of cancer as well.

In addition to its work on imetelstat, Geron also has several other programs focused on developing new treatments for cancer and other diseases. These include programs focused on small molecule inhibitors and RNA-based therapeutics.

Overall, Geron is an innovative biopharmaceutical company dedicated to improving outcomes for patients with hematologic myeloid malignancies through groundbreaking research into new treatments like imetlelstat. With its commitment to advancing science and improving patient care, Geron is poised to make significant contributions in the fight against cancer and other diseases.

Website
geron.com
Address
149 commonwealth drive
Categories
Biotechnology